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2Abstract
In this review we discuss the role of environmental and pharmacological treatments 
to enhance cognition with special regards to neurodevelopmental related disorders 
and aging. How the environment influences brain structure and function, and the 
interactions between rearing conditions and gene expression, are fundamental 
questions that are still poorly understood. We propose a model that can explain 
some of the discrepancies in findings for effects of environmental enrichment on 
outcome measures. Evidence of a direct causal correlation of nootropics and 
treatments that enhanced cognition also will be presented, and possible molecular 
mechanisms that include neurotrophin signaling and downstream pathways 
underlying these processes are discussed. Finally we review recent findings 
achieved with a wide set of behavioral and cognitive tasks that have translational 
validity to humans, and should be useful for future work on devising appropriate 
therapies. As will be discussed, the collective findings suggest that a combinational 
therapeutic approach of environmental enrichment and nootropics could be 
particularly successful for improving learning and memory in both developmental 
disorders and normal aging.
Keywords: Cognitive impairment, nootropics, environmental enrichment, neuro 
developmental disorders, Ras-ERK pathway
3I. Introduction
Cognitive impairment affects a significant part of the population (~ 1 in 20 people in 
the United States)(NIH, Center for Disease Control). Apart from the direct effects of 
the impairments on the individual and their ability to function in society, there are 
also significant emotional and financial burdens on family members, and increased 
costs for education, health care, and personal care. As a result, there has been a 
concerted effort to develop therapies that can benefit people with cognitive 
impairment. Because impairments to cognition can arise from a number of factors 
including gene defects as occurs in some neurodevelopmental disorders, adult 
related diseases, injuries, or with normal aging, some therapies may be too restricted 
(i.e., targeting a specific protein associated with a gene defect) and only useful for 
some types of cognitive problems associated with these conditions. However, it is 
possible that other types of therapies may generalize to several types of disorders or 
conditions associated with cognitive dysfunction and may be useful for both mild and 
sever forms of dysfunction. It is expected that these types of therapies would have 
their primary actions on fundamental pathways that are known to subserve learning 
and memory and other aspects of cognition.
The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th 
version) defines six neurocognitive domains: perceptual and motor function, 
language, learning and memory, social cognition, attention and executive function 
(Sachdev et al., 2014). Cognitive abilities are given by the sum of these domains or, 
more accurately by the functional sum of each subdomain: 1) Visual perception, 
visuo-constructional reasoning, perceptual and motor coordination, 2) Object 
naming, word finding, verbal fluency, grammar and syntax and receptive language, 
3) Free and cued recall, recognition memory, semantic and autobiographical 
(episodic) memory and implicit learning, 4) Recognition of other individual’s emotions 
and intentions, 5) Sustained, divided or selective attention and speed of processing, 
and 6) Planning and decision-making, working memory, inhibition and flexibility. 
Obviously, these domains do not work in an isolated fashion but as a complex and 
integrated system and lay on the very same substrate, the CNS. Hence a great deal 
of understanding and insight has come from pathological manifestations involving 
the CNS. Moreover, convergent pieces of information have pointed scientists to 
different strategies to enhance cognition for both the pathological and the healthy 
individual. Of these approaches, environmental enrichment and pharmacological 
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and learning are particularly compelling.
This review will first cover considerations of behavioral approaches that are 
being used in preclinical research for higher-order cognitive domains such as 
executive functions, attention, working and episodic memory, and social skills 
targeted for assessing the effects of drugs or gene functions. Then, a working model 
will be presented aimed towards explaining how environmental enrichment can have 
different effects in mutant mouse models of disorders. We will offer an example of 
how environmental enrichment rearing for the fragile x model mouse results in some 
positives outcomes for synaptic plasticity but also reveals greater morphological 
deficits for dendritic spines than previously described. Recent work using a class of 
nootropics that positively modulate AMPA receptors (Ampakines), and increase 
neurotrophin levels, for improving several features of associated with aging including 
declines in neuronal health, synaptic plasticity, and behavior will be discussed.  
Finally, other work on a neurotrophin associated Ras-ERK pathway that is an 
important biological translator of environmental adaptations will be presented, as well 
as recent drugs that target it. A common thread for the effects of the nootropics that 
will be described is that they work on key points in at least one converging pathway 
involved in cognition.
II. How to Address Higher-Order Cognitive Dysfunctions in Preclinical 
Research with Clinical Translational Validity
Despite the fact that language is a characteristic cognitive domain of the human 
species, although some language-like functions have been mimicked in rodents 
(Haddon and Killcross, 2007), much of our knowledge comes from pre-clinical 
studies investigating the other 5 cognitive domains. Doubtlessly, understanding 
higher cognitive functions often presents the biggest challenge as it has some 
hidden pitfalls. Let us make the example of an archer whose objective is to strike an 
arrow to hit a moving target. Its success will depend on: its ability to hold the bow 
steady, its sight and only finally on its cognitive ability to generate and update a 
visuospatial map to calculate the arrow trajectory. A similar approach should be used 
to better interpret preclinical studies (Figure 1). Thus, it goes without saying that 
when a manipulation (e.g. a mutation, a drug or a treatment) gives for an instance a 
motoric manifestation, this will indeed affect spatial memory performance, whether or 
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behaviors would also be expected (Bannerman et al., 2014). This of course does not 
imply that there could not be deficits in higher cognitive functioning without physical 
conditions nor that anxiety is required for these deficits to manifest.
Cognitive impairments in neurodevelopmental disorders are early features 
(Elvevag and Goldberg, 2000; Goldman-Rakic, 1994; Owens and Johnstone, 2006; 
Papaleo et al., 2012), long-lasting traits and strong prognostic predictors of patients’ 
functional outcomes in the everyday life (Linsell et al., 2015; Troyb et al., 2016). 
Thus, cognitive deficits have some of the most critical impact on patients, their 
families and the entire public health system (Dziwota et al., 2018; Klietz et al., 2018; 
Lee et al., 2017; Mueser and McGurk, 2004). Notably, therapeutic interventions 
aimed towards cognitive deficits are still non-optimal, presenting huge variable 
responses between patients. Furthermore, the most largely used drugs for these 
disorders, such as antipsychotic drugs produce only small neurocognitive 
improvements if considering the entire population. Again, cognitive responses to 
antipsychotic drugs show marked inter-individual variability, and the mechanistic 
basis of such unpredictable variability is still scarcely known.
The development of more efficient treatments for cognitive disabilities are 
difficult to implement also because we still have an incomplete understanding of the 
heterogeneity, risk factors, neural circuitry and related mechanisms involved. This is 
particularly difficult to dissect in the clinical setting where a number of factors 
increase the complexity of the interpretation of the results including, for example, 
genetic/clinical heterogeneity, gene-by-gene, gene-by-environment and gene-by-
environment-by-pharmacological treatments interactions. In this context, in vivo 
mechanistic studies in mouse models can be informative. In particular, genetic, 
environmental and pharmacological factors can be strictly controlled and available 
cutting-edge genetic tools allow for addressing mechanisms in a very high circuit- 
and cell-specific manner. In mouse models, environmental, genetics, developmental 
factors and all their interactions can be strictly controlled. Moreover, a number of 
fast-growing mechanistic tools are available to sort out causal relationships between 
phenotypes studied (e.g. classical, time- and site-specific conditional 
knockouts/knockins and transgenics, ENU, CRISPR, TALENs, ZFNs, 
chemogenetics, optogenetics). However, cognitive studies in rodents must not rely 
only on classical and easier assessments but must adopt properly designed tasks 
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the best proof of predictive/translational validity is to assess healthy human subjects 
and/or human patients in equivalent tasks that are suggested to be modeled by the 
rodents’ studies and confirm a similar outcome. Of course, we should be always 
cautious in not anthropomorphizing too much the observations made about mouse 
behavior, but it is mandatory to try to integrate, as much as possible, findings from 
rodents with equivalent human evidence. Otherwise, there is the risk that the mere 
use of too simplistic and often inappropriate behavioral tasks in rodent studies, 
despite very elegant and complex molecular and circuit-based techniques adopted, 
might fall short in its clinical impact. This has been part of the major causes of many 
clinical trial failures, and the related withdrawal of a number of pharmaceutical 
companies from neuroscience research (Nutt and Goodwin, 2011).
In the following sections, we will illustrate some approaches in preclinical 
research that we believe are better suited to address higher-order cognitive domains 
such as executive functions as defined by the NIMH Research Domain Criteria 
(RDoC), working and episodic memory, attentional control, and social cognition. 
These are all cognitive functions particularly disrupted in neurodevelopmental 
disorders (Barch and Ceaser, 2012; D'Souza and Karmiloff-Smith, 2017; Leavitt and 
Goldberg, 2009; Lesch, 2014, 2016; Mahdi et al., 2018; Ouhaz et al., 2018; Ross et 
al., 2006). This kind of classification is in line with, and expands previous reviews on, 
the topic of how to address cognitive deficits with cross-species validity (Cope et al., 
2016b).
Cognitive control
Cognitive control abnormalities, also termed under the umbrella “executive 
functions”, are among the main key features of neurodevelopmental disorders such 
as autism spectrum disorder (ASD), Intellectual Disability (ID), attention deficit 
hyperactivity disorder (ADHD) and schizophrenia (Boxhoorn et al., 2018; 
Conzelmann et al., 2016; Ehlis et al., 2011; Filipe et al., 2018; Garon et al., 2018; 
Hronis et al., 2017; Joyce et al., 2002; Karalunas et al., 2018; Kerns et al., 2008; 
Lifshitz et al., 2016; Managó et al., 2016; More and Jensen, 2014; More et al., 2017; 
Ouhaz et al., 2018; Scheggia et al., 2014; Sidorov et al., 2018; Weinberger et al., 
1986). Cognitive control deficits also are described for individuals with prefrontal 
7cortex lesions suggesting that the frontal lobe system area is critically important for 
this behavior (Miller and Cohen, 2001).
Experimentally, cognitive control can be measured by so-called “attentional 
set-shifting tasks”. A classic and widely used task is the Wisconsin Card Sorting 
Task (WCST) (Berg, 1948; Eling et al., 2008), while a more recent and refined task is 
the “intra- and extra-dimensional attentional set-shifting” of the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) (Barnett et al., 2010; 
Roberts et al., 1988) (Table 1). Impairments in the ability to shift an attentional set 
(measured by Extra Dimensional Shift stages) are sensitive measures of frontal 
cortices-related executive control deficits. (Owen et al., 1993; Scheggia et al., 2014; 
Scheggia et al., 2018). The human WCST and Intra Dimensional/Extra Dimensional 
tasks have been successfully modeled and validated in rodents (rats and mice) 
confirming that the measures of cognitive control assessed rely on mostly conserved 
neural substrates in humans, monkeys, rats and mice (Birrell and Brown, 2000; 
Bissonette et al., 2008; Brown and Bowman, 2002; Dias et al., 1996; McAlonan and 
Brown, 2003; Owen et al., 1993; Rahman et al., 1999; Robbins, 2007; Roberts et al., 
1988; Scheggia et al., 2014).  The first example of such a task in rodents was the so-
called attentional set-shifting “digging task”, developed for rats and then validated for 
mice (Birrell and Brown, 2000; Bissonette et al., 2008; Papaleo et al., 2008). An 
automatic version of the task is now available that reduces time, increases reliability, 
replicability, and standardization, and is useful for large-scale genetic and/or drug-
screening studies with proven predictive validity in healthy human and patients with 
schizophrenia studies (Scheggia et al., 2014; Scheggia et al., 2018).
Working memory
The definition of working memory regards the type of memory that is active and 
relevant only for a short period of time, while performing complex tasks such as 
reasoning, comprehension and learning. The major components of working memory 
implicate a short-term memory storage and a complex multimodal manipulation of 
these memories in order make an action based on a determined rule or need 
(Baddeley, 2010; Managó et al., 2016; Scheggia et al., 2012).
Several paradigms are used to test working memory functions in humans with 
the most used being the N-Back task (Callicott et al., 2000), and the spatial delayed 
response tasks (Barch et al., 2012). Equivalent tasks employed in rodents with high 
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paired-trial variable-delay alternation task, the 8-arm radial maze “delayed non-
match to sample” or ‘‘win-shift’’, the 8-arm maze “random foraging task”, the odor 
span tasks, and some paradigms of delayed matching and delay non-matching to 
sample position operant conditioning tasks (Aultman and Moghaddam, 2001; 
Dudchenko, 2004; Dunnett, 1993; Floresco et al., 1997; Kellendonk et al., 2006; 
Papaleo et al., 2014b; Papaleo et al., 2008; Papaleo et al., 2012; Sannino et al., 
2015; Seamans et al., 1995; Seamans and Phillips, 1994; Young et al., 2007). Data 
gathered from mouse studies in these tasks have proven to be predictive of 
equivalent human findings. For example, using the T-maze discrete paired-trial 
variable-delay alternation task in mouse models, it has been shown that a very 
similar mouse-human functional non-linear epistatic interaction between the 
catechol-O-methyl transferase (COMT) and dysbindin-1 genes was evident at the 
level of activity in the prefrontal cortex in healthy human subjects performing a N-
Back working memory task (Papaleo et al., 2014a, b; Papaleo et al., 2008).
Similarly, this specific T-maze paradigm predicted COMT-by-sex-dependent 
interactions in healthy subjects performing the N-Back working memory task and 
related cortical anatomy (Papaleo et al., 2014b; Sannino et al., 2015). To note, 
genetic human effects in the N-Back task performance correlated with genetic 
mouse performance in the discrete paired-trial T-maze testing with variable delays 
between 4 and 60 seconds (Papaleo et al., 2008) and (Sannino et al., 2015), as well 
as the acquisition itself of the task with an inter-trial delay of 4 seconds (Papaleo et 
al., 2014a). Effects on the acquisition of this specific discrete paired-trial alternation 
task are likely due to the link between working memory and prefrontal cortex function 
(Kellendonk et al., 2006). While not exhaustive, these examples provide evidence of 
efficient approaches for more predictive translational research.
Episodic Memory
Episodic memory is the memory of events and experiences that can be recalled in 
relation to a specific time and in proper order (Tulving, 2002). The main components 
of episodic memory are, in an integrated way, the “what”/”who”, “when”, and “where” 
(WWW) a past experience occurred. This is distinguishable from the other form of 
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information and general facts. For humans, episodic memory can be investigated 
using interview or self-report, although this can be problematic in individuals with 
disorders/diseases that affect their ability to verbally communicate since scoring 
depends on a high amount of detail (Ben Shalom, 2003; Cheke and Clayton, 2013).  
Thus, a number of tests have been used in human studies most of which are WWW 
retrospective and prospective tests (Loftus and Davis, 2006).
Episodic-like memory in rodent studies also has been extensively assessed 
using WWW tests (Dere et al., 2005; Kart-Teke et al., 2006). Combining 
neuroanatomical methods with the WWW tests also have been useful for delineating 
the involvement of brain structures to the specific components of this type of memory 
(e.g., hippocampus is needed for “what”, “when”, and “where”, whereas medial 
prefrontal cortex is needed only for “where”) (DeVito and Eichenbaum, 2010). 
Another task that is often used to capture the animal’s awareness of the relationship 
between objects (what) and their spatial locations (where), is the hippocampal-
dependent Object Location task (Barker and Warburton, 2015). This task has been 
used in numerous studies evaluating mouse models of cognitive disorders, including 
developmental and aging-related disorders, and preclinical testing of therapies 
therein (Contestabile et al., 2013; Contestabile and Sintoni, 2013; Karamihalev et al., 
2014; Manago et al., 2016; Ricciarelli et al., 2017; Seese et al., 2014b; Seese et al., 
2014c). Finally, with regard to disorders, it is important to consider that deficits in 
episodic memory can reflect impairments either in the encoding or the retrieval of the 
information. Therefore, the inclusion of tasks that examine how animals sample the 
environment during learning may also be useful for preclinical studies. To this end 
learning paradigms which are self-directed, non-reinforced, and allow for the 
assessment of an animal’s behavior in relation to different aspects of the 
environment over time may be particularly useful.
Attention
Attentional control is the ability to select specific available cues for preferential 
processing, while ignoring competing information (Smid et al., 2006). There are 
different subtypes of attention such as sustained attention, selective/focused 
attention and divided attention (Millan et al., 2012). Common available tasks to 
measure attentional abilities in humans are the Continuous Performance Test (CPT) 
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(Cornblatt et al., 1988; Gold et al., 2012; Gold and Thaker, 2002; Nuechterlein and 
Dawson, 1984), the CPT-Identical Pairs (CPT-IP) (Cornblatt et al., 1988), the A-X 
CPT versions (Servan-Schreiber et al., 1996), the Stroop task (MacLeod, 1991; 
Stroop, 1935; Zvyagintsev et al., 2013) and the Spatial Attentional Resource 
Allocation Task (SARAT) (Hahn et al., 2006a). For rodents, discrete elements of 
attentional processes such as sustained and focused attention, impulse control, 
perseverative and reactivity-related functions can be effectively studied. In particular, 
one of the most effective and extensively used task in rodents is the 5-Choice Serial 
Reaction Time Task (5-CSRTT) which allows for measures of general attention, 
impulse control and processing speed (Carli et al., 1983; Ciampoli et al., 2017; 
Huang et al., 2017; Mereu et al., 2017; Robbins et al., 1993; Robbins, 2002; Voon et 
al., 2014). Conversely, the Distractor Condition Sustained Attention Task (dSAT) and 
the 5-Choice Continuous Performance Test (5C-CPT) are operant –based tasks 
developed as signal-detection tasks first in rodents (Barnes et al., 2012; Bushnell, 
1999; Ciampoli et al., 2017; Huang et al., 2017; McGaughy and Sarter, 1995; Mereu 
et al., 2017; Mohler et al., 2001; Nuechterlein et al., 2009; Young et al., 2009) and 
then redesigned for humans, providing clinical translatability (Demeter et al., 2008; 
Young et al., 2013). Similarly, based on the proven utility of the SARAT paradigm in 
distinguishing deficits in selective attention from broad monitoring alterations relevant 
to schizophrenia (Hahn et al., 2012; Hahn et al., 2006b), equivalent tasks have been 
developed in both adult and adolescent mice (Ciampoli et al., 2017; Huang et al., 
2017; Mereu et al., 2017). Overall, all of these tasks represent useful tools for 
bridging preclinical and clinical research focused on attention.
Social Cognition
Fundamental to all social interactions, the mutual understanding of social information 
is primarily achieved with the ability to perceive, process and interpret facial and 
body expression of emotions. This biologically innate ability, defined as “social 
cognition”, has a widespread implication in the development of social connection and 
cooperation, in the evaluation of truthfulness/deception, in shaping individual 
success and personal care, and in national security and intelligence. Social skill 
domains can be categorized into emotional processing, social perception, social 
knowledge, theory of mind and attributional bias (Billeke and Aboitiz, 2013; Green 
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and Horan, 2010; Green and Leitman, 2008; Green et al., 2005; Green et al., 2008; 
Managó et al., 2016; Millan and Bales, 2013).
Emotion recognition tasks are the most-extensively used paradigms to assess 
human social cognition (Green et al., 2015; Henry et al., 2016; NIH). Due to the high 
complexity of the measures used to study social cognition in humans it is difficult to 
create translationally-valid tasks for rodents. Nonetheless, mice are a social species 
that exhibits complex social behaviors hence measures of social ability are often 
taken from home-cage observations such as maternal/parental behaviors, colony 
formation/hierarchy, interactions between peers, nest-building, sleeping together in 
the nest or resting in group huddles (Green et al., 2005; Millan and Bales, 2013).
Moreover, the basic assessment of social interaction abilities in rodents involves 
measurements of specific behaviors such as sniffing, following, climbing on, 
ultrasonic vocalizations, allogrooming, fighting, and sexual behavior while two 
unfamiliar adults freely interact in an open-field arena (Bambini-Junior et al., 2014; 
File and Hyde, 1978; File and Seth, 2003; Hirsch et al., 2018; Huang et al., 2014; 
More, 2008; Silverman et al., 2010). Under these settings, many genetic, 
pharmacological, developmental and neurobiological rodent models have been 
shown to exhibit perturbations in social interaction (Hida et al., 2013; Koros et al., 
2007; Millan and Brocco, 2008; Peleg-Raibstein et al., 2012; Pratt et al., 2012; 
Sams-Dodd, 1999). These social interaction abnormalities are usually interpreted to 
be relevant to the social withdrawal phenotypes associated with developmental 
disorders including ASD, depression and schizophrenia. Beyond this, other studies 
have explored the possibility of testing more specific social cognition 
endophenotypes such as the animal’s ability to encode, retrieve/recognize and 
respond appropriately to social stimuli (Millan and Bales, 2013; Silverman et al., 
2010). Such tasks may provide more relevant information on social deficits present 
in neuro-developmental disorders.
In general though, sociability in rodents is widely tested using the three-
chamber task (Crawley, 2000; Kaidanovich-Beilin et al., 2011; Moy et al., 2007; 
Papaleo et al., 2011; Roullet and Crawley, 2011; Young et al., 2011). Another widely 
used procedure is the “habituation/dishabituation” paradigm (Dluzen and Kreutzberg, 
1993; Huang et al., 2014; Winslow and Camacho, 1995). Moreover, social motivation 
components can be tested in operant chambers, where a rodent is trained to press a 
lever with access to a conspecific as a social reinforcer (Evans et al., 1994). 
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However, despite their extensive use, most of these tasks are limited in their 
equivalence to human clinical tasks to address social cognition. The evaluation of 
social cognitive processes such as theory of mind, facial perception/recognition, and 
gaze-following are tested in non-human primates (Machado and Nelson, 2011; 
Millan and Bales, 2013). A notable exception is a few seminal studies that did show 
the transmission of pain/fear responses from one rodent to a familiar observer 
(Burkett et al., 2016; Langford et al., 2006; Pisansky et al., 2017; Sterley et al., 
2018), reminiscent of empathy or consolation, or social buffering. However, 
consistent efforts in the field are still required with a clear aim to prove the predictive 
translational validity of novel and more refined social cognitive tasks in rodents.
III. The Importance of Assessing Developmental Trajectories
Higher order cognitive functions exhibit different trajectories through the life-span, 
from their establishment and maturation during development through their decline 
with age (Gutchess, 2014). For example, significant improvements in higher-order 
cognitive functioning appear from childhood to adolescence, with the most significant 
changes in the development of attentional control, processing speed, decision 
making, planning, and response inhibition (Anderson, 2001; Brodeur and Enns, 
1997; Casey et al., 2008; Davidson et al., 2006; Deoni et al., 2011; Ernst et al., 2011; 
Gold and Thaker, 2002; Rosso et al., 2004; Yurgelun-Todd, 2007; Zvyagintsev et al., 
2013). On the other hand, in the course of normal aging there are marked declines in 
cognition including deficits in working memory and long-term memory (Park and 
Reuter-Lorenz, 2009). Because of these age-related changes in behavior, there are 
several things that must be considered with regard to assessing the efficacy of 
treatments, including both pharmaceutical and environmental enrichment 
approaches. First, when should treatments commence (i.e., at what age, that also 
would not have negative effects particularly for drug therapies) and how long should 
they be given? Are multiple treatments needed for greater outcomes? Importantly, 
what endpoint measures should be assessed that are the most informative? These 
fundamental questions are often difficult to address in a single study, primarily 
because they involve many variables that need to be controlled. Another key 
problem that investigators face is understanding how the anatomical, physiological, 
and behavioral changes that normally occur with development and aging relate to 
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each other, as a basis for then investigating how they are influenced by such things 
as pathology and genetic mutations, as well as potential treatments.
In the context of neurodevelopmental disorders, it is important to note that many are 
known to be caused by, or highly associated with, genetic mutations (Kasem  et al., 
2018; Leung and Jia, 2016; Penagarikano et al., 2007; Ramaswami and Geschwind, 
2018; San Martin and Pagani, 2014). Genetic variations can severely impact brain 
maturation (e.g., dendritic morphologies and spine densities, cell number) and 
related developmental processes (including cognition) that ultimately result in the 
appearance of psychiatric-related behavioral dysfunction. For example, for genetic 
risk conditions such as the 22q11.2 deletion syndrome (with high penetrance of 
ADHD and schizophrenia) specific neurocognitive developmental lags across 
different ages have been found, consistent with greater gray matter loss and 
accelerated cortical thinning during childhood and adolescence (Eliez et al., 2000; 
Gothelf et al., 2008; Gur et al., 2014; Jalbrzikowski et al., 2013; Kates et al., 2004; 
Kates et al., 2001; Schmitt et al., 2015; Simon et al., 2005). In addition, a number of 
longitudinal clinical studies have demonstrated abnormal cognitive processes that 
were correlated with cortical maturation pathologies in other disorders such as ASD 
and schizophrenia. These include psychomotor and ideomotoric functioning, verbal 
processes, perseveration, cognitive rigidity, attention and perception (Docx et al., 
2014; Eliez et al., 2000; Gothelf et al., 2008; Jalbrzikowski et al., 2013; Karalunas et 
al., 2017; Kates et al., 2004; Kates et al., 2001; Moffitt et al., 2015; Muetzel et al., 
2018; Sannino et al., 2017; Schmitt et al., 2015; Simon et al., 2005). To further 
complicate the picture is some recent evidence indicating that people with 
schizophrenia, although they do not exhibit delay-dependent deficits (Gold et al., 
2010), have impairments in selective attention, working memory and executive 
function that seem to represent distinct defects instead of different manifestations of 
one higher-order impairment. Although measures of top-down control of selective 
attention, working memory and executive function seem all intercorrelated, 
substantial evidence indicates that working memory and executive function are 
separate sources of variance (Gold et al., 2018).
These findings have increased emphasis on the need to assess 
developmental trajectories for various disorders relative to controls with the hope of 
better refining diagnostic and intervention strategies, and possibly identifying 
pertinent markers for early interventions.
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In contrast to human work, preclinical rodent studies assessing developmental 
trajectories in relation to genetic vulnerability factors are more limited. Most often, 
animal work relies on using genetically engineered mutant mouse lines that are 
generally treated and then evaluated or tested in adulthood. Moreover, treatment 
interventions are most often given to animals in adulthood when the abnormal 
phenotype is fully developed, rather than during early critical developmental periods 
when neuronal connections are being wired, and thus more likely to be malleable 
and responsive to treatments. As stated above, understanding the changes that 
occur during development, and how a specific gene defect affects this, is crucial for 
deciding when to assess pharmacological and environmental strategies for 
enhancing cognition in the context of neurodevelopmental disorders with a high 
genetic component. In addition, it is important to note that apart from genetic defects, 
many other types of manipulations have been used to show that a vast array of early 
developmental challenges result in profuse long-term neural and cognitive effects 
(such as on dendritic spine density, brain volume, and attention and working 
memory) that last well into adulthood; when delayed or presented in adulthood, 
similar manipulations have less pronounced effect. Such manipulations include brain 
insults during gestation, parturition or the early postnatal period, as well as altered 
maternal care and post-weaning isolation, maternal malnutrition and vitamins 
deficiencies, or early pharmacological treatments (Cope et al., 2016a; Cope et al., 
2016b; Lipska et al., 2002a; Lipska et al., 2002b; Lipska et al., 1992; Lipska et al., 
2001; Pennucci et al., 2016).
Another key factor in preclinical work that one needs to consider when 
assessing the ontogeny of higher-order cognitive functions in rodents are the tools, 
which need to accommodate the more limited developmental windows in rodents as 
compared to humans. Important available tools are developmental milestones 
assessments developed for mice (Ricceri et al., 2004; Scattoni et al., 2006; Scattoni 
et al., 2009; Scattoni et al., 2005), which give basic knowledge on development of 
physical features. In relationship to higher order cognitive functions, some recent 
implementation of the 5CSRTT for adolescent mice could be useful for assessing 
control of attention (Ciampoli et al., 2017; Remmelink et al., 2017; van Enkhuizen et 
al., 2014). However, other work is needed to better develop the preclinical battery of 
tasks able to consistently address higher order cognitive function development in 
adolescent and pre-adolescent rodents.
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Finally, with regard to pertinent treatments for neurodevelopmental disorders, 
it is important to consider the genetics of individual patients rather than the overall 
heterogeneous population, similar to what has been already achieved with 
chemotherapeutic strategies in cancer genomics for personalized medicine (Boyer et 
al., 2016; Hermens et al., 2006; Jellen et al., 2015; Lim et al., 2015; Riazuddin et al., 
2017). Genetic factors are known to play a critical role in a variety of behaviors, 
including cognition and the pathogenesis of psychiatric illnesses (Bespalov et al., 
2012; Bespalova and Buxbaum, 2003; Papaleo et al., 2012; Scheggia et al., 2018). 
Moreover, genetic variations can also moderate the variable responses to 
pharmacological and intervention strategies based on both pharmacodynamics and 
pharmacokinetics mechanisms (Hanson and Madison, 2010; Hu, 2012; Siniscalco et 
al., 2012; Smoller, 2014). A recent example on this emerging field, and specifically 
related to cognitive control with mouse-human cross-species validation, is evidence 
that a common and functional genetic variation that reduces the expression of the 
dysbindin-1 gene stratifies subjects whose executive functions better respond to 
antipsychotics medications (Scheggia et al., 2018). Similar approaches should be 
explored and applied also in the context of developmental disorders, to deliver more 
effective intervention strategies.
IV. Genes and Environment: Towards a Model for Effects on Behavior
Epigenetic mechanisms dynamically regulate the transcription and expression of 
genes throughout life and are responsive to environmental changes. The 
transcription of DNA into mRNA is influenced by epigenetic marks that are abundant 
both inside or around these genes regions; DNA methylation and histone 
modifications are the most studied epigenetic processes, but also noncoding RNAs 
including microRNAs have a substantial role (Akbarian and Huang, 2009; Moore et 
al., 2013; Pishva et al., 2014; Yu et al., 2012). Current evidence suggests that these 
epigenetic processes can be altered by life experiences such are environmental and 
social rearing conditions. For example, in a recent study, young mice that had 
experienced two months of environmental enrichment were found to have regionally 
specific effects on DNA methylation and transcription within hippocampus (Zhang et 
al., 2018).
As expected from epigenetic modifications, it is clear that environmental 
enrichment leads to marked changes in gene expression in brain. One of the best 
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examples of this is for the Brain derived neurotrophic factor (BDNF), in which 
increases in both mRNA and protein for this neurotrophin have been observed in 
hippocampus and other brain regions of animals exposed to environmental 
enrichment (Baroncelli et al., 2010; Cowansage et al., 2010; Nithianantharajah and 
Hannan, 2006; Simpson and Kelly, 2011a). BDNF, acting via the TrkB receptor, 
promotes dendritic growth and increases spine density in an ERK1/2-dependent 
manner (Cowansage et al., 2010). Thus, many of the effects of environmental 
enrichment such as increased dendritic spinogenesis, enhanced synaptic plasticity 
(both Long-term potentiation and Long-term depression), and increased learning and 
memory and cognitive flexibility could be due to increases in BDNF protein content 
and enhancement of BDNF-trkB signaling; other findings using BDNF heterozygous 
mice further supports this idea (Novkovic et al., 2015; Rossi et al., 2006).
While it is widely known that environmental enrichment enhances cognition 
and dendritic spine density in mammals (Correa et al., 2012; Fischer, 2016; 
Hakansson et al., 2017; Karelina et al., 2012; Sampedro-Piquero and Begega, 2017; 
Sansevero et al., 2016; Schuch et al., 2016), the contributions of the various aspects 
of the environment are not well understood for each phenotype that has been 
studied. Environmental enrichment typically is comprised of three domains being (I) 
increased physical activity, that is usually provided by a running wheel and a bigger 
house cage, (II) increased social groupings, and (III) increased opportunities for 
exploration (i.e. larger environments relative to standard housing conditions) and 
interactions with novel objects such as toys (Sztainberg and Chen, 2010; Wood et 
al., 2011). Of these components of environmental enrichment, some have shown 
that increased physical activity per se seems to provide most of the beneficial effects 
(Brown et al., 2003; Kobilo et al., 2011; Lazarov et al., 2010; van Praag et al., 1999, 
2000). Although lifelong enrichment in the absence of exercise also has profound 
effects on reversing age-related declines in recognition, spatial and working memory 
(Birch and Kelly, 2018), suggesting that both the social and somatosensory 
components also contribute to the positive effects of enrichment. Finally, the effects 
of social versus the non-social (novelty, exercise, etc.) components of enrichment 
are also dissociable by several measures including brain weight that is more 
responsive to environment complexity than social conditions (Rosenzweig et al., 
1978), and differential effects on impulsivity, behavioral flexibility, and memory 
(Prado Lima et al., 2018; Wang et al., 2017).
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In spite of the overall effect that environmental enrichment can have, the 
fundamental designs used by laboratories for social, physical, somatosensory 
enrichment are generally not uniform. Studies also often differ in animal strain, sex, 
and types of controls used (e.g., isolated vs group standard-housed controls) (for full 
review, see (Simpson and Kelly, 2011b)) that can further complicate findings and 
lead to varied outcomes between laboratories. It cannot be overstated that for any 
experimental design, consideration of the control groups is paramount; for 
enrichment paradigms, differences between control animals that have been socially 
isolated versus those that have social experience from group housing needs to be 
considered since this may confound interpretations of the social vs non-social 
aspects of the enrichment effects. Furthermore, another complication to many 
preclinical studies assessing the effects of enrichment on a mouse model of a 
disease or disorder, is the specific manipulation of the genome in a mutant mouse 
model. It is not surprising then that studies have given ambiguous and often 
contrasting results on the efficacy and effectiveness of interventions and therapies 
performed in mouse mutants to human conditions (Ciammola et al., 2017; Daumas 
et al., 2017; Gao et al., 2018; Shi et al., 2017; Woodbury-Smith et al., 2017). While 
these discrepancies might indeed be attributed to the dramatic epigenetic 
modifications as described above, it does not fully explain the differences across 
laboratories.
Based on these issues, we propose a working model that the degree of 
response to environmental enrichment is limited by (I) the underlying neurobiology of 
the experimental subjects (i.e., control vs genetic mutation, or disease state) and (II) 
the variations in the type and amount of enrichment. Thus, differences in either of 
these two components might have very different outcome on cognitive functions. 
This model is more heavily influenced by the different computational power between 
a functional CNS and that one of a relevant mutant, than enrichment itself. For 
example, in the case of ID in which processing of environmental information or cues 
are perturbed, this subject’s capacity for processing experiences in a mild 
enrichment paradigm may already be at its maximal limit. Thus, any further increase 
in the type of level of enrichment would not have any further effect in the mutant as 
compared to wild type (Figure 2). On the other side of the spectrum, any long-lasting 
stress-induced increase in cortisol levels could have deleterious effects that 
outweigh any genetic resilience (Barfield and Gourley, 2018). However, an 
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impoverished environment might also elicit genotype differences depending on the 
genetic mutations and whether the specific gene affected in the mutant offers 
resilience to such conditions in the wild type. This idea is borne out for a model of 
non-syndromic ID, the Gdi1-null mouse, which did not show the expected cognitive 
impairment when housed in mildly enriched environments but only when housing 
was a mildly impoverished environment (Bianchi et al., 2009; D'Adamo et al., 2014; 
De Giorgio, 2017). This may be explained by the neurobiology of the Gdi1-null 
mutant that curtails the benefit it can get from environmental enrichment, in spite of 
an increased number of dendritic spines this environment elicits in the brain (Correa 
et al., 2012; Daumas et al., 2017; Hunter et al., 2017): In Gdi1-null mice the pre-
synaptic recycling of glutamatergic vesicles remains time-limited, hence the 
beneficial effects of enrichment remain curtailed and ineffective on some sustained 
tasks (Bianchi et al., 2009; D'Adamo et al., 2014; Ezaki and Nakakihara, 2012; More 
et al., 2017; Strobl-Wildemann et al., 2011). Finally, it is important to note that the 
proposed outcomes of this model also would be influenced by the age at which 
enrichment began, and the duration of exposure. To this point, studies suggest that 
the effectiveness of enrichment increases when provided early in life and with long 
duration (Freret et al., 2012; Simpson and Kelly, 2011a).
In consideration of this working model to explain effects of environmental 
enrichment, both syndromic and non-syndromic rodent models of ID are the most 
prominent examples for the physiological limitations in the response to different 
forms of enrichment (D'Adamo et al., 2014). In the following section we will describe 
one of these cases for ID, the Fragile X mouse model, and the influence of 
environmental enrichment on dendritic morphology and synaptic plasticity.
Environmental enrichment treatment in the Fragile X syndrome mouse model: an 
example
Fragile X syndrome (FXS), the most common form of inherited ID, is generally 
caused by an expansion of CGG-repeats in the Fmr1 gene that encodes Fragile X 
Mental Retardation Protein (FMRP) which silences the gene (Penagarikano et al., 
2007). FMRP has been shown to regulate protein synthesis in dendritic spines, and 
its loss results in abnormal levels of many synaptic proteins (Chen et al., 2010; 
Muddashetty et al., 2007; Schütt et al., 2009; Todd et al., 2003; Zalfa et al., 2003). 
Aligning with the synaptic protein defects, a well-described feature of FXS is the 
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presence of “immature” dendritic spines in neocortex. Specifically, pyramidal cell 
dendritic spines are more numerous, with a greater proportion being long and thin, 
than in cognitively normal individuals (Hinton et al., 1991; Rudelli et al., 1985). As 
spines are thought to be the site of functional changes that mediate memory storage, 
an immature morphology could represent the critical effect of the FXS mutation 
underlying learning impairments in this disorder. If this is the case, then the degree 
to which the spines are adaptable to morphological change and can be driven 
towards maturation in the FXS condition is an important question to explore for 
developing strategies to improve cognition and behavior.
The Fmr1 knockout (KO) mouse model of FXS exhibits many phenotypes of 
the human condition including learning impairments (Brennan et al., 2006; 
Consortium, 1994; D'Hooge et al., 1997; Ventura et al., 2004; Zhao et al., 2005), 
greater impulsivity (Moon et al., 2006), and a predisposition for seizures (Chen and 
Toth, 2001; Musumeci et al., 2000; Yan et al., 2004). In addition, Fmr1 KOs exhibit 
abnormally high numbers of long-thin spines and greater spine densities in 
neocortex (Comery et al., 1997; Galvez and Greenough, 2005; Hayashi et al., 2007; 
McKinney et al., 2005; Su et al., 2011) as seen in human studies. Consistent with the 
learning and spine morphology deficits, the mutants also have deficits in long-term 
potentiation (LTP) in both hippocampus (Hu et al., 2008; Lauterborn et al., 2007; Lee 
et al., 2011; Shang et al., 2009; Yun and Trommer, 2011) and cortex (Larson et al., 
2005; Li et al., 2002; Meredith et al., 2007; Zhao et al., 2005). Because of the strong 
phenotypic correspondence between the human condition and the mouse model, the 
Fmr1 KO has been widely used in the field to investigate the relationship between 
spine morphology defects, synaptic plasticity deficits, and learning impairments in 
the disorder, and for testing therapeutic strategies aimed at improving outcomes for 
individuals with FXS.
Much work in the Fmr1 KO has focused on the hippocampal CA1 field where 
discrete LTP deficits have been reported (Lauterborn et al., 2007), and pronounced 
defects in the signaling mechanisms that regulate the spine actin cytoskeleton to 
support hippocampal LTP (Chen et al., 2010; Seese et al., 2012). In sum, loss of the 
FMRP protein results in defective signaling in the pathway involving the small 
GTPase Rac that engages p21-activated kinase to promote filamentous actin 
stabilization in dendritic spines (Chen et al., 2010; Lauterborn and Gall, 2017; Rex et 
al., 2009). Because of the signaling defect, LTP at these synapses is slow to 
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stabilize leaving it vulnerable to disruption for a longer period of time as compared to 
wild types (Chen et al., 2010; Lauterborn and Gall, 2017). Given these marked 
defects in the actin cytoskeleton machinery needed for synaptic reorganization in 
hippocampus, it is surprising that studies on dendritic spine abnormalities in this 
structure in the KO have been mixed (Bilousova et al., 2009; Braun and Segal, 2000; 
Grossman et al., 2006; He and Portera-Cailliau, 2012; Levenga et al., 2011; Pop et 
al., 2012; Segal et al., 2003; Su et al., 2011; Swanger et al., 2011).
To investigate the degree to which spine abnormalities occur in the adult 
Fmr1 KO hippocampus, and to test whether spine morphologies might be normalized 
by environmental enrichment rearing as had been reported for neocortex (Meredith 
et al., 2007; Restivo et al., 2005), as study was conducted using 3-dimensional (3D) 
reconstructions of green fluorescent protein (GFP) expressing CA1 hippocampal 
neurons (Lauterborn et al., 2015). Beginning at weaning (21 days postnatal) KOs 
and wild types were either reared in an enriched environment or in standard 
laboratory cages until 3 months old; the enriched housing system consisted of 
multiple rooms, bedding, a habit trail system, running wheel, and other small objects. 
Analyses of CA1 hippocampal neurons revealed only modest differences between 
spine measures for Fmr1 KO and wild type mice that were provided standard 
housing, with the exception of spine head volumes that were reliably lower in the 
mutants and consistent with findings for neocortical neurons (Irwin et al., 2000). 
Rearing in the enriched environment did not attenuate this difference; rather, it 
revealed greater effects of the FXS mutation on dendritic arborisations and spines of 
adult hippocampal neurons. Enrichment resulted in wild type mice exhibiting 
significantly greater numbers of higher order branching than did Fmr1 KOs, although 
average dendritic lengths were similarly increased in both genotypes receiving 
environmental enrichment relative to standard housing. Rearing in enriched 
environment did not correct spine head volumes in the Fmr1 KO: mean spine head 
volume was approximately 40% lower in KOs than in wild types under both housing 
conditions. However, rearing conditions did affect total spine length with enrichment 
normalizing mean spine length in the mutants. These findings suggest that with the 
FXS mutation certain spines features such as length may be more malleable to the 
influence of environment, whereas others such as spine head size are not. Given the 
strong correlative evidence that spine head volume and structure is coupled to 
synaptic function (Bosch and Hayashi, 2012; Lynch et al., 2007), these findings also 
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suggest that therapies which target spine actin cytoskeleton regulatory proteins may 
be particularly effective for FXS, and other developmental ID disorders characterized 
by spine morphology defects.
The above results suggest that rearing environment alone is not sufficient to 
overcome spine morphology defects in FXS. Yet, rearing environment and BDNF 
application each have been shown to influence the effect of the Fmr1 mutation on 
LTP. In particular, Fmr1 KO mice reared in an enriched environment reportedly have 
normal cortical potentiation, comparable to levels seen in wild type mice housed in 
standard cages (Meredith et al., 2007). This suggests that environmental enrichment 
might reverse or offset cellular disturbances underlying some impairments in 
synaptic plasticity and learning in the FXS mutants and in the human condition. The 
effects of rearing environment in the Fmr1 KO on hippocampal LTP or hippocampal-
dependent behaviors have yet to be tested. However, application of exogenous 
BDNF to hippocampal slices fully restores LTP in the mutants (Lauterborn et al., 
2007), suggesting that drug approaches which enhance neurotrophin expression 
may be beneficial for treating hippocampus-dependent behaviors in individuals with 
the fragile X mutation. Ampakines are a good example of such an approach as they 
increase neuronal BDNF expression (see section below). While current work is 
testing this possibility in the mouse model, it is important to note that not all 
neurodevelopmental disorders may be amendable to this type of intervention. 
Notably, recent studies have shown that semi-chronic ampakine treatment in the 
BTBR mouse strain, that exhibits behaviors aligning with some of the major 
diagnostic criteria of ASD, did not improve their memory performance in the 
hippocampus-dependent object location task (Seese et al., 2014a).
A final important consideration with regard to treatment for 
neurodevelopmental disorders, as discussed earlier, is the age at which animals are 
exposed to environmental enrichment, and the length of exposure. It is clear for 
Fmr1 KOs that environmental enrichment rearing beginning at weaning age was not 
sufficient to normalize spine measures. However, recent work has shown that early 
social enrichment starting at the time of birth rescued some behaviors and induced 
some maturational changes in CA1 hippocampal spines in the Fmr1 KO (Oddi et al., 
2015). More striking improvements on brain maturation and hippocampal function 
were reported for the Ts65Dn mouse model of Down Syndrome, another form of ID, 
following early enrichment with both enhanced social (maternal) care and a housing 
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environment that included options for exploration and physical activity, and novelty 
(Begenisic et al., 2015). Thus, early intervention may be key to better outcomes for 
individuals with developmental disabilities, and is consistent with a recent study 
describing positive outcomes for two young FXS children that received intensive 
educational interventions combined with several different drug treatments beginning 
at two years of age (Winarni et al., 2012).
V. A Pharmacological Approach Toward Improving Cognition
Cognitive function is ultimately dependent on its capacity for growth and establishing 
appropriate neuronal connections. There are many factors that play a role in this but, 
at minimum, it relies on sufficient neuronal activity and appropriate engagement of 
synaptic proteins and signaling cascades to promote the establishment and 
strengthening of synaptic contacts. Just as sensory stimuli from the environment 
ultimately have effects on brain through activation of neuronal circuits, one can take 
advantage of this by using drugs that enhance neuronal activity. One such example 
of this are ampakines, which have been shown to be cognitive enhancers 
(nootropics) and hold great promise as potential therapeutics for a number of 
conditions with memory impairment including Alzheimer’s disease, Huntington’s 
disease, schizophrenia, menopause, developmental intellectual disabilities, and 
aging. In the next section, we will focus on normal aging to illustrate how daily 
treatments with an ampakine in combination with environmental enrichment can 
forestall the deleterious effects of brain aging, with striking effects on neuronal 
cytoarchitecture and behavior. 
Ampakines and Environmental Enrichment effects on brain ageing: an example
Positive modulators of the glutamatergic α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor were identified nearly 35 years ago as 
having positive effects on learning and memory in rodents, including in conditions of 
impaired cognition function (Cumin et al., 1982). Variants of these compounds (e.g., 
lower impact ones, such as CX516, that have greater safety) also have been tested 
in humans and evaluated in clinical trials for several different conditions including 
schizophrenia, mild cognitive impairment, and fragile X among others (Berry-Kravis 
et al., 2006; Boyle et al., 2012; Goff et al., 2001; Johnson and Simmon, 2002; Oertel 
et al., 2010; Wezenberg et al., 2007) (see also ClinicalTrials.gov).  Ampakines are a 
23
specific class of positive allosteric AMPA receptor modulators that have been shown 
to not only facilitate learning and the synaptic mechanisms thought to underlie 
memory formation (Lynch et al., 2014; Lynch and Gall, 2006), but also promote 
neurotrophin (BDNF) expression in forebrain and protect neurons from 
neurodegeneration (Bahr et al., 2002; Lauterborn et al., 2009; Lauterborn et al., 
2000; Rex et al., 2006; Simmons et al., 2011).
Ampakines are small molecules that bind at the dimer interfaces of AMPA-
type glutamate receptors (Jin et al., 2005) and modulate the ligand-bound receptors 
by slowing their deactivation and desensitization rates (Arai et al., 2000). Together, 
these two effects on the AMPA receptor prolong the open time of the ion channel 
and increase the amplitude and duration of fast, excitatory transmission (Lynch and 
Gall, 2006). The ampakine-induced enhancement of excitatory postsynaptic currents 
lowers the threshold for LTP, a form of synaptic plasticity thought to underlie learning 
and memory (Staubli et al., 1994).  Moreover, in cases where LTP has been shown 
to be deficient such as in rodent models of Huntington’s disease, Angleman 
syndrome, and low estrogen, treatment with certain variants of the ampakines 
markedly improves synaptic plasticity (Baudry et al., 2012; Kramár et al., 2012; 
Simmons et al., 2009). As predicted from the effect on LTP, ampakines have been 
shown to enhance learning in both healthy normal rodents (Hampson et al., 1998) 
and humans (Ingvar et al., 1997), as well as in models of cognitive impairment 
(Baudry et al., 2012; Simmons et al., 2009). In addition, beyond direct effects of 
ampakines on excitatory transmission, these compounds also up-regulate the 
neuronal expression of BDNF (Lauterborn et al., 2000; Rex et al., 2006; Simmons et 
al., 2011; Simmons et al., 2009), a neurotrophin which has been shown to support 
neuronal survival and differentiation in brain (Conner et al., 1998), and is critical for 
LTP and learning (Lynch et al., 2014). Importantly, periodic dosing with ampakines is 
sufficient to elevate BDNF protein levels in hippocampus and neocortex that can be 
maintained for days (Lauterborn et al., 2009; Lauterborn et al., 2003; Simmons et al., 
2011). It is the dual action of ampakines, both the immediate effects on AMPA 
receptor currents and the enduring increases in BDNF protein levels well beyond 
drug half-life, which make these compounds particularly intriguing for use as long-
term therapeutics for maintaining neuronal health and function.
Recent work has begun to address the question of whether long-term 
ampakine treatment could be beneficial by assessing if this treatment regimen 
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offsets the deleterious effects of brain aging in hippocampus (Lauterborn et al., 
2016). In these studies, 10-month old middle-aged rats were treated with the 
ampakine CX929 (5 mg/kg in 10% honey in water) or vehicle orally on a 5 day-on / 2 
day-off schedule for three months and housed in an enriched environment during 
this period. The enriched housing bin was multi-tiered and contained a nest box, 
bedding, running wheel, chewable items, and novelty items that were changed 
weekly. Enrichment was given to both vehicle and ampakine treated animals to avoid 
possible negative effects of impoverished living associated with standard housing, 
and to test the effects of the compounds in a situation that is closer to what humans 
experience daily (i.e., environmental novelty and complexity, physical activity).
Effects of CX929 treatment on behavior were particularly striking, with the 
ampakine improving both long-term memory and self-organizing behavior. For these 
studies an unsupervised learning paradigm was used in which animals were allowed 
30 min to freely explore a large arena that was divided into “rooms” containing 
unique objects and had an attached home box, and their forays beginning from the 
home box through arena space were analyzed; this task is self-directed, non-
reinforced. Middle-aged rats receiving ampakine or vehicle were initially tested in the 
apparatus beginning 5 weeks following the initiation of drug treatment to assess 
changes in their behavior, and then reassessed 4, 7, and 14 days later to evaluate 
long-term memory of the complex environment; testing was prior to the daily CX929 
treatment to preclude circulating drug effects. For both groups of rats, the average 
numbers of forays in the apparatus were similar on the first day of testing. On 
subsequent test days the ampakine treated rats exhibited a marked reduction in total 
number of forays, whereas the vehicle group did not show this pattern and numbers 
of forays remained high even with the additional experience. A potential confound to 
these findings could be if the CX929 had affected arousal, but measures of distance 
travelled during explorations were not different between drug and vehicle treated 
groups suggesting little to no effect on arousal. Likewise, ampakine treated rats did 
not exhibit anxiety related behaviors such as preference for darken spaces or 
preference for being near walls as opposed to open spaces in the arena; both 
measures were equivalent between ampakine and vehicle treated groups. The 
results suggest that the change in exploration across days for the CX929 group 
reflected enhanced learning during the initial session that did not occur in the vehicle 
treated group. Next, it was evaluated whether there were differences in the 
25
movement patterns between the two groups of rats within the arena using a Markov 
sequence analysis; using this technique, predictions errors were calculated for an 
animal's location at different times in the future based on probabilities from its own 
past behavior for single transitions between sites within the arena (van der Heijden 
et al., 1990). These analyses revealed that the prediction errors for ampakine treated 
rats were significantly less than vehicle treated rats across the testing days, 
indicating that CX929 treatment helped to organize the exploratory behavior of the 
middle-aged rats into predictable patterns. Finally, consistent with the improvements 
in behavior, there were also marked improvements in hippocampal CA1 LTP and a 
restoration of neuronal cytoarchitecture, including increased dendritic branching and 
spine growth, in the CX929-treated rats. 
The collective findings suggest that ampakine treatment may be useful for 
restoring neuronal structure and function, and improving spatial working memory that 
declines with aging (Lester et al., 2017). Importantly though, the results also 
demonstrate that the drugs are well-tolerated for several months and the positive 
effects last at least through the period of treatment in otherwise “normal”, albeit 
middle-aged animals. Thus, the groundwork is now set for similar types of preclinical 
studies in young animals to test the utility of long-term nootropic treatment combined 
with environmental enrichment for a wide-range of neurodevelopmental disorders. 
Targeting the Ras-ERK pathway for improving cognitive functions
Ras-ERK signaling activation in the adult mammalian brain is a necessary step to 
establish both long-term plasticity and long-term memories (such as hippocampus 
dependent spatial reference memory and context fear conditioning), as conclusively 
demonstrated in a number of electrophysiological and behavioral studies (Davis and 
Laroche, 2006; Thomas and Huganir, 2004). The Ras-ERK pathway is engaged by 
several classes of neurotransmitter receptors and tyrosine kinase receptors, such 
the BDNF receptor TrkB, to regulate changes in gene expression and protein content 
(Figure 3). Thus, there are several potential routes whereby this signaling pathway 
can be modulated, to either increase or decrease its activation, including factors that 
influence BDNF levels and TrkB signaling or directly affect downstream kinase 
function.
Work of the last two decades indicates that aberrant Ras-ERK signaling in the 
brain may lead to forms of ID, suggesting that inappropriate signaling in the CNS has 
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a detrimental effect on a wide variety of human tests on associative learning and 
spatial and non-spatial learning and memory (Borrie et al., 2017; Fasano and 
Brambilla, 2011). For instance, gain of function germline mutations upstream in the 
ERK pathway, including oncogenic variants of the RAS genes and deficiency in 
neurofibromin, the product of the neurofibromatosis type 1 (NF1) gene, can lead to a 
plethora of neurodevelopmental disorders collectively indicated as RASopathies 
(Ehninger et al., 2008; Rauen, 2013; Tidyman and Rauen, 2009). These syndromic 
disorders include NF1 (neurofribromin gene), Noonan syndrome (NS, mainly 
PTPN11, SOS1 and KRAS genes), Costello syndrome (CS, HRAS gene), cardio-
facio-cutaneous syndrome (CFC, mainly BRAF, KRAS and MEK1/2 genes), and 
Legius syndrome (LS, SPRED1 gene) (Rauen, 2013). While RASopathies are 
heterogeneous, they are characterized by a series of common manifestations 
including cardiac and cutaneous defects, craniofacial dysmorphism, and increased 
probability of developing benign tumors. Moreover, the majority of these disorders 
share a variable degree of ID, from mild to severe (San Martin and Pagani, 2014). In 
addition, loss of function mutations in the SYNGAP1 gene, coding for a brain specific 
Ras-GAP, have been associated to sporadic, non-syndromic ID forms in 
approximately 4% of screened cases (Hamdan et al., 2011; Hamdan et al., 2009; 
Krepischi et al., 2010).
A major turn in our understanding of the neural mechanisms associated to 
RASopathies and other Ras-ERK dependent ID forms came from recent evidence in 
rodent models, strongly supporting the notion that mental dysfunction may be 
caused by an imbalance in excitation/inhibition in the brain (Costa-Mattioli, 2014; 
Costa et al., 2002; Cui et al., 2008; Fasano and Brambilla, 2011; Papale et al., 
2017). On one side, in mouse models of both mild (e.g. NF1, LS) (Costa et al., 2002; 
Cui et al., 2008) and more severe forms of ID such as Noonan Syndrome KRASG12V 
(Fasano and Brambilla, 2011; Papale et al., 2017) behavioral impairments such as 
episodic memory in the novel object recognition (NOR) task, reference and working 
memory in the 8-arm radial maze and T-maze and hippocampus dependent 
associative learning are linked to an increase in GABA inhibition; for Noonan 
Syndrome in humans, strong activating mutations in KRAS are predictive of an ID 
phenotype (Carta et al., 2006; Niihori et al., 2006; Schubbert et al., 2006; Stark et al., 
2012; Zenker et al., 2007). On the contrary, other mutations associated to milder 
forms of Noonan Syndrome (Ptpn11-SHP2) (Lee et al., 2014) and SYNGAP1 
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associated ID (Aceti et al., 2015; Clement et al., 2012; Clement et al., 2013; Ozkan 
et al., 2014) manifested enhanced excitatory activity. The exact cause of such 
opposing alterations in the activity of either excitatory or inhibitory neurons is 
essentially unknown. Moreover, while in some mouse models of these disorders, and 
in a subset of NF1 patients, treatments with Ras-ERK inhibitors in the adult stage 
may temporarily ameliorate the cognitive symptoms- such as hippocampus and non-
hippocampus dependent forms of associative learning- (Ahmed et al., 2010; Cui et 
al., 2008; Lee et al., 2014; Li et al., 2005; Mainberger et al., 2013), in other cases it 
remains unclear whether cellular changes (i.e. synaptic maturation) occurring during 
post-natal development become essentially irreversible in the adult and may require 
earlier interventions (Clement et al., 2012; Papale et al., 2017).
Understanding the cellular mechanisms affected by specific mutations in the 
Ras-ERK pathway could play a crucial role in developing stratified/personalized 
clinical interventions. As our working model for effects of environmental enrichment 
indicates, the discriminant factor for a successful therapy is the severity of the 
pathological state which is directly related to the gene mutation found in the patient 
to be treated. However, unlike environmental enrichment, a pharmacological 
approach can be highly selective and targeted based on the cellular pathways 
involved. Moreover, such an approach clearly has advantages for potentially 
reducing side effects and resulting in greater gain of function. An additional 
advantage of targeting directly the Ras-ERK pathway is that such an approach could 
also ameliorate non-cognitive, peripheral deficits, as recently described (Hernandez-
Porras et al., 2014).
Direct tests of Ras-ERK inhibitors in the conditional KRASG12V mouse model 
of Noonan Syndrome have been conducted with an effort in treating the cellular 
phenotypes (i.e. GABAergic synaptogenesis) (Papale et al., 2017; Papale et al., 
2016). Importantly though, the pharmacological interventions were only successful 
when given during early postnatal development, presumably coinciding with the 
developmental window in which Ras-ERK activity is still high and inhibitory synapses 
are completing their maturation. By contrast, treatments in the adult were not 
effective, probably due to the GABA synaptogenetic process already being 
completed, and relatively lower ERK signaling, by this point.
Recently, two drugs affecting the Ras-ERK cascade were developed and 
validated, the small molecule MEK inhibitor PD325901 and the cell permeable 
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peptides (CPP) RB1/RB3 was recently reported (Papale et al., 2016). These two 
drug classes have been tested in the conditional KRASG12V model and are also very 
efficient in blocking cocaine mediated behavioral responses in a mouse model of 
drug addiction (Papale et al., 2017; Papale et al., 2016). PD325901 is particularly 
promising in that it is the only clinically relevant MEK inhibitor currently available that 
passes through the blood brain barrier and it has been tested in several clinical trials 
for cancer (NCT00147550, NCT00174369, NCT02297802, NCT01347866, 
NCT02022982, NCT02039336, NCT02510001 NCT020096471). However, 
PD325901, similarly to other MEK inhibitors, is a rather toxic compound and may not 
be ideal for prolonged symptomatic treatments, especially in children and teens. An 
alternative would be to clinically develop cell permeable peptides that have been 
suggested to be potentially more tolerable, possibly because their IC50 is more in 
the micromolar rather than nanomolar range (Papale et al., 2017; Papale et al., 
2016).
A major central point that should be taken into account for devising an 
effective treatment of RASopathies with Ras-ERK inhibitors is the severity of the 
mutation involved and the corresponding temporal profile of ERK activation. Recent 
work has clearly pointed to the hypothesis that more severe mutations (e.g. KRAS) 
may lead to accelerated phenotypes, at least in the brain, with a therapeutic window 
shifted to the juvenile state. Late interventions for severe forms of RASopathies may 
not work simply because the Ras-ERK pathway becomes normalized. On the other 
hand, milder phenotypes like those observed in NF1 patients may instead result in 
incomplete penetrance and a wider temporal intervention window, thus allowing for a 
treatment also at the adult stage. In addition to those differences, which should be 
considered during patient recruitment and trial design, it is also relevant to highlight 
the fact that while an early intervention in severe forms of RASopathies may lead to 
a permanent “cure” it is possible that a late intervention might only result in 
symptomatic amelioration.
Altogether the evidence leads us to believe that approaches based on Ras-
ERK inhibition may not be only viable for RASopathies but also for other forms of ID 
and ASD. More specifically, MAPK3, the gene coding for ERK1, lies in recurrent 
copy number variants (CNVs) at chromosome 16p11.2 (deletions more frequent than 
duplications, altogether around 1-3 cases in 10,000 people in the general population) 
which have been associated with ASD, ID and other neurodevelopmental disorders 
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including schizophrenia, whilst the ERK2 (MAPK1) gene lies within a second 
recurrent CNV associated with learning disabilities and schizophrenia at 
chromosome 22q11.2. Importantly, while deletions and duplications at the 16p11.2 
locus span many genes, studies integrating common genetic associations and 
expression data, known as transcriptome wide association (TWAS), have highlighted 
a wider role for MAPK3 also in non CNV carriers. Specifically, and consistent with 
duplication of MAPK3 found in 16p11.2 increasing liability to schizophrenia, there is 
genome-wide significant evidence for an association between increased brain 
expression of MAPK3 and schizophrenia (Gusev et al., 2018).
Chromosome 16p11.2 CNV contains at least 27 genes, making it a formidable 
task to devise an effective stratified therapy. However, it has been previously shown 
that in a mouse model of the 16p11.2 chromosomal deletion, ERK activity is 
enhanced (Pucilowska et al., 2015). This observation is in line with a model of 
regulation of ERK signaling which supports a distinct role of ERK1 and ERK2 
kinases in governing overall ERK signaling. Whereas ERK2 kinase is the main 
transducer of downstream signal, ERK1 plays a role of fine negative modulator. This 
is corroborated by the evidence that a decrease in ERK1/ERK2 ratio enhances while 
the opposite attenuates global ERK signaling, with corresponding alterations in 
physiological and behavioral responses (Indrigo et al., 2010; Mazzucchelli et al., 
2002; Vantaggiato et al., 2006). Consistent with this view, our recent work in the 
above-mentioned mouse model of the 16p11.2 deletion showed that treatment with 
selective ERK pathway inhibitors during gestation can permanently rescue 
anatomical and behavioural phenotypes such as episodic-like memory (in the NOR 
test), and hippocampus dependent spatial reference and working memory (Davis, 
1995; Pucilowska et al., 2018; Pucilowska et al., 2015). Furthermore, treatment in 
adult mice also showed amelioration of the above behavioral symptoms (Pucilowska 
et al., 2018). This strongly supports the view that gene dosage impacting on the ERK 
pathway contributes to phenotype of the 16p11.2 CNV and that compounds targeting 
the ERK pathway may represent an effective therapeutic intervention. Finally, 
elevated ERK activity has been reported for the Fragile X mouse mutant, the Fmr1 
KO (Wang et al., 2012), and the Ras-ERK inhibitor lovastatin has been shown to 
improve behavior in children and adults with FXS (Caku et al., 2014). It is thus 
possible to envision that pharmacological treatment with a Ras-ERK inhibitor may be 
useful for amelioration of attention and working memory deficits, and a rescue of the 
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molecular and cellular phenotypes, in a number of developmental disorders with 
disparate etiology.
VI. Future Directions
Therapies that combine environmental enrichment with those that promote neuronal 
activity and signaling (e.g. Ras-ERK pathway selective) and/or facilitate BDNF (e.g., 
ampakines), could prove to be a particularly useful approach for improving learning 
and memory in multiple forms of cognitive impairment including those that emerge 
during early development and with aging. Further work is needed though to 
understand the degree to which improvements can be made on dendritic spine 
defects and for cognitive/behavioral impairments across different disorders or 
conditions of impairment, and treatment regiments that are most effective. To this 
point, work with ampakines suggests that daily treatment is tolerable and effective for 
improving outcomes in adult animals, although further work is needed to assess if 
similar treatments are also beneficial in pre-weanling animals and without unwanted 
effects on the developing nervous system. As BDNF expression (Friedman et al., 
1991; Timmusk and Metsis, 1994) and activation of the key dendritic spine actin 
regulatory protein cofilin (Lauterborn et al., 2017) both emerge in rat brain by the 
second postnatal week, this period may represent an optimal point at which the 
initiation of treatments could be most effective for modulating glutamatergic 
synapses and promoting neurotrophin expression during development. Importantly, 
work with Ras-ERK compounds in one mutant model of ID suggests early 
interventions are likely critical for correcting deficits associated with cognitive 
impairment that emerge in development (Papale et al., 2017; Papale et al., 2016; 
Ruiz-DeDiego et al., 2018). Positive outcomes would further support the idea of early 
interventions for most individuals with developmental intellectual disabilities to fully 
correct spine defects by the time they reach adulthood.
An alternative strategy could involve other key components of the 
downstream TrkB receptor. One of these is the nuclear kinase mitogen- and stress-
activated protein kinase 1 (MSK1), which has gained considerable interest in the 
field of cognitive enhancement. MSK1 has been identified as a link between cell-
surface neurotransmitter receptors and the gene expression necessary for long-term 
memory (Choi et al., 2017; Karelina et al., 2012; Karelina et al., 2015). MSK1 exerts 
its physiological effects by coupling the activation of BDNF receptors to the 
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regulation of transcription via the phosphorylation of CREB (Daumas et al., 2017; 
Hunter et al., 2017), and due to its position within the nucleus, could be a more 
precise target for a putative nootropic. MSK1’s role is central for homeostasis in 
response to environmental changes and is highly involved in environmental-induced 
synaptic transmission effects via its action on immediate early gene activity-
regulated cytoskeletal protein Arc/Arg3.1 (Correa et al., 2012; Daumas et al., 2017; 
Hunter et al., 2017).
For the adult brain, aging, and age-related cognitive disorders (e.g., 
Alzheimer’s disease), future work is also needed to address when is the most 
optimal time to begin treatments that are the most beneficial. The work described 
here for one pharmacological approach indicates that beginning treatment during 
middle age does have profound effects at least through a relative short period in the 
animal’s life thereafter. But whether these changes can be sustained and tolerated 
through long-term aging is not known. Additional work is needed to evaluate these 
questions for the effectiveness of both environmental enrichment and nootropics.
Finally, for studies aimed at evaluating drugs and other therapies including 
environmental enrichment on cognition, several other important factors need to be 
considered. The first is the behavioral approaches that are used in preclinical 
research for higher-order cognitive domains such as executive functions and working 
memory, and how predictive they are for humans. Second, is the choice of 
enrichment for the animal (e.g., opportunity for intense physical activity; animals 
socially housed; novelty introduced on a regular basis) sufficient and complex 
enough for inducing changes in the brain. This is an important consideration for 
studies using mutant mice, as mild forms of enrichment may not be sufficient to (i) 
see a positive effect on phenotype or, conversely, (ii) reveal the full phenotypic 
capacity that is needed for then evaluating the effectiveness of therapeutic 
compounds.
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Figure Captions
Figure 1. Higher cognitive functions are influenced by the underlying mnemonic, 
emotional and health status of the subject in exam.
Figure 2. Proposed model for how wild type (WT) and ID mouse models differ in 
response to the level of environmental enrichment, leading to genotype differences 
in neuronal effects (e.g., neuronal cytoarchitecture, synaptic plasticity) and cognitive 
behavior. Under this model, greater enrichment results in larger phenotypic 
differences between WT and ID mouse models, primarily due to greater responsivity 
under the WT condition. In contrast, environmental deprivation would be expected to 
negatively influence both genotypes, potentially leading to a floor effect. As 
discussed more fully in the main text, differences in enrichment, especially between 
laboratories, can lead to the possibility of inconsistent behavioral tests results as 
often observed and reported in the literature. Deprived environment: e.g., social 
isolation (1 mice / cage) and no other enrichment; Impoverished environment: e.g., 2 
mice/cage without cardboard tubes nor toys; Standard environment: e.g., 4 
mice/cage cardboard tubes, toys and tunnels; Environmental enrichment: e.g., 8 
mice / rat sized cage, running wheel, cardboard tubes, toys, tunnels. 
Figure 3. The Ras-ERK pathway implements neuronal adaptations such as protein 
synthesis and modulation of synaptic connections in response to environmental 
changes and can be the target for several types of nootropics. The schematic 
depicts some key components of the Ras-ERK pathway. A variety of mechanisms 
can activate Ras proteins such as glutamate NMDA receptors and calcium signaling, 
G-protein-coupled receptors (e.g., dopamine receptor D1R) or tyrosine kinase 
receptors (TRK). Membrane signals converge toward Ras exchange factors RAS-
GFR, SOS and Ras-GRP that activate RAS proteins; the docking protein GRB2 and 
adapter protein SHC facilitate receptor activation of Ras. In the cytoplasm, the 
protein kinase cascade is then initiated by sequential activation of RAF, MEK and 
MAPKs of the ERK family to elicit nuclear transcription (red arrows); note that ERK 
can also affect protein synthesis via other routes as well (e.g. S6K). Once 
translocated into the nucleus, MAPKs can phosphorylate transcription factors such 
as CREB that leads to expression of immediate early genes (IEGs) such as c-Fos. 
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Some of these products are themselves transcription factors and might induce late 
response genes (LRGs). It has been proposed that MSK1 and ERK 1/2 might have 
opposing effects on the transcription factor CREB and Histone H3 phosphorylation 
leading to further fine tuning of gene expression. Protein kinase A (PKA) and C 
(PKC) can activate this cascade in a fashion that is independent from Ras, thus 
providing an additional level of regulation. As shown (blue asterisks) several classes 
of nootropics can target key points that either initiate the pathway (e.g., ampakine-
induced increases in the neurotrophin BDNF and enhanced TRK signalling) or are in 
the pathway (MEK inhibitors) to regulate Ras-ERK signalling and downstream 
protein synthesis; up- or down-regulation of the pathway would depend on the 
individual intellectual disability defect. Appropriate levels of protein synthesis are 
needed for long-term modulation of synaptic contacts and for memory formation and 
consolidation.
Table 1. Commonly-used tasks to investigate higher-order cognitive domains in 
humans versus similar type studies in rodents. We acknowledge that these tests 
might not be equivalent between the two species in probing the specific domains.
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1	
	
Table 1 
Widely-used Human tasks Widely-used Rodent tasks 
Cognitive Control 
1. Wisconsin Card Sorting Task (WCST) 
2. “intra- and extra-dimensional attentional 
set-shifting” of the Cambridge 
Neuropsychological Test Automated 
Battery (CANTAB) 
 
1. Attentional set-shifting “digging” task 
2. Stuck in set 
 
Working Memory 
1. n-back task 
2. Spatial delayed response task 
3. List sorting 
 
1. T-maze discrete paired-trial variable-
delay alternation task 
2. Spontaneous alternation 
3. 8-arm radial maze “delayed non-match 
to sample” or ‘‘win-shift’’ task 
4. 8-arm maze “random foraging task” 
5. Odor span tasks 
6. Delayed matching and delay non-
matching to sample position operant 
conditioning tasks 
7. Simultaneous stimulus processing 
 
Episodic Memory 
1. Interview or self-report 
2. “what, when, where” tasks 
 
1. Novel object recognition 
2. Object location task 
3. Object in place 
4. Temporal order discrimination 
 
Attention 
1. Continuous Performance Test (CPT) 
2. CPT-Identical Pairs (CPT-IP)  
3. A-X CPT versions 
4. Spatial Attentional Resource Allocation 
1. 5-Choice Serial Reaction Time Task (5-
CSRTT) 
2. Distractor Condition Sustained Attention 
Task (dSAT) 
2	
	
Task (SARAT) 
 
Social Cognition 
1. Emotion recognition tasks 
2. Self-report inventories 
1. Observations of maternal/parental 
behaviors, colony formation/hierarchy, 
peer interactions, nest-building, 
sleeping/resting in group huddles 
2. Observations of social interactions 
between two unfamiliar animals, 
including sniffing, following, climbing 
on, ultrasonic vocalizations, 
allogrooming, fighting, and sexual 
behavior 
3. Three-chamber social approach task 
4. “habituation/dishabituation” paradigm 
5. Place conditioning – social stimuli 
6. Appetitive conditioning – social stimuli 
 
 
